Results 151 to 160 of about 48,656 (208)

Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐PD‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Anti‐programmed death 1 (PD‐1) and anti‐programmed death ligand 1 (PD‐L1) immune checkpoint inhibitors (ICIs) have changed the treatment landscape of many advanced malignancies. However, immune‐related adverse events (irAEs) bring great challenges to clinical benefits. The prediction of irAEs is urgently demanded for early detection
Panpan Jiao, Lijuan Xue, Weijuan Tan, Quan Chen, Shan Lin, Min Song, Chunling Ma, Juan Zhan   +7 more
wiley   +1 more source

A Case Report of a Multisystemic Immune‐Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha‐1

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune‐related adverse events (irAEs) after treatment with sintilimab (PD‐1 inhibitor) in combination with thymosin alpha‐1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
Ting Li, Bao‐Liang Wu, Cai‐Long Yu, Liang‐Yan Jin   +3 more
wiley   +1 more source

Single‐cell sequencing for cancer precision medicine: From mechanism discovery to diagnosis and therapeutics

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Single‐cell sequencing overcomes bulk sequencing limitations, enabling high‐resolution multi‐omics analysis at the single‐cell level. It reveals tumour heterogeneity, identifying key subpopulations and tumour microenvironment interactions driving progression and resistance.
Yue Zhao, Hancong Li, Huanzuo Yang, Gongshuang Zhang, Xinyue Fu, Peiheng Li, Puxing He, Shuang Wu, Han Luo   +8 more
wiley   +1 more source

GPR183‐mediated activation of PI3K is a potential biomarker for immunotherapy in lung cancer

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Anti‐PD1 treatment and PI3Kγ inhibition had remarkable therapeutic performance on CD4+ Tcm and CD4+ Tn in lung cancer through potential regulation of PI3K pathway with participation of GPR183. Abstract Background As one of commonly used immune checkpoint inhibition therapies, PD1 monoclonal antibodies exhibit a promising cancer immunotherapy approach ...
Ling Ye, Nannan Zheng, Fangming Liu, Huirong Fu, Yifei Liu, Ying Yang, Ruixue Qi, Duojiao Wu, Lin Shi, Dongli Song   +9 more
wiley   +1 more source

CEACAM6 silencing suppresses tumour growth and sensitises cholangiocarcinoma to cisplatin

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
CEACAM6 has the potential to become a novel and independent prognostic biomarker in cholangiocarcinoma (CCA). Silencing CEACAM6 can inhibit CCA tumour growth and significantly enhance the chemosensitivity to cisplatin. This chemo‐sensitising effect is mediated through the disruption of ribosome biogenesis and impairment of DNA damage repair.
Shi‐Jia Dai, Jiang‐Qi Tan, Jia‐Qi Guo, Ya‐Nan Zhou, Teng Huang, Hao‐Lin Jiang, Yang Liu, Li‐Wei Dong, Zhen‐Gang Yuan   +8 more
wiley   +1 more source

Porous polyethylene in reconstructive head and neck surgery [PDF]

, 1985
Berghaus, Alexander
core   +1 more source

Beyond bacterial defences: the role of lysozyme in cancer

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
Lysozyme (LYZ) is a multi‐functional secreted factor that encompasses both antibacterial and immunomodulatory functions. Emerging evidence highlights its complex role in tumour progression by directly influencing tumour cells and modulating the immune microenvironment.
Lei Wang, Qian Dong, Fuchu He, Zhiwen Gu, Aihua Sun   +4 more
wiley   +1 more source

Prognostic Significance of Circulating Immune Subset Counts in Nasopharyngeal Carcinoma

ImmunoTargets and Therapy
Honghui Xie,1– 3,* Lin Zhang,1,3,4,* Lizhi Chen,5,* Wenchao Zhou,1,6 Lijuan Zhang,1,3 Yong Su,1– 3 Bocheng Li,1,6 Peng Ding,1,6 Yun Xiao,1– 3 Tianzhu Lu,1,2,4,7 Xiaochang Gong,1,2,4,7 Jingao Li1,2,4,7 1NHC Key Laboratory of ...
Xie H, Zhang L, Chen L, Zhou W, Zhang L, Su Y, Li B, Ding P, Xiao Y, Lu T, Gong X, Li J   +11 more
doaj  

Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer [PDF]

, 2018
Bilimoria, Blanchard, Geara, Gugic, Haque, Haque, Haque, Haque, Koussis, Liu, Liu, McMillan, Moreno, Moye, Peters, Pignon, Siddiqui, Stahl, Sun, VanderWalde, Verma, Verma, Verma, Verma, Verma, Wang, Wu, Xiao, Zeng   +28 more
core   +2 more sources

deltaHED predicts survival and immune evasion in PD‐1 blockade therapy: A multi‐cohort study across three cancer types

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
deltaHED predicts survival and immune evasion in PD‐1 blockade therapy: a multi‐cohort study across three cancer types. deltaHED quantifies germlinesomatic HLA‐I divergence and predicts survival and immune evasion in PD‐1 blockade therapy. Across nasopharyngeal carcinoma, melanoma, and esophageal squamous cell carcinoma, high deltaHED is associated ...
Jianying Xu, Xiaoli Wei, Jicheng Yao, Ujjwal Mukund Mahajan, Ulf Dietrich Kahlert, Run Shi, Kaiying Zhang, Ahmed Alnatsha, Zhengyi Qian, Fei Han, Fenghua Wang   +10 more
wiley   +1 more source